Seagen Gestion

Gestion contrôle des critères 2/4

Le PDG Seagen est David Epstein, nommé en Nov2022, a un mandat de 1.08 ans. La rémunération annuelle totale est $ 58.59M, composée du salaire de 0.3% et des bonus 99.7%, y compris les actions et options de la société. détient directement 0.009% des actions de la société, d'une valeur de $ 3.75M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.4 ans et 9.9 ans.

Informations clés

David Epstein

Directeur général

US$58.6m

Rémunération totale

Pourcentage du salaire du PDG	0.3%
Durée du mandat du directeur général	1.1yrs
Propriété du PDG	0.009%
Durée moyenne d'occupation des postes de direction	2.4yrs
Durée moyenne du mandat des membres du conseil d'administration	9.9yrs

Mises à jour récentes de la gestion

Recent updates

Seagen Inc.'s (NASDAQ:SGEN) Popularity With Investors Is Under Threat From Overpricing

Dec 12

A Look At The Fair Value Of Seagen Inc. (NASDAQ:SGEN)

Apr 17

Here's Why We're Not At All Concerned With Seagen's (NASDAQ:SGEN) Cash Burn Situation

Mar 20

An Intrinsic Calculation For Seagen Inc. (NASDAQ:SGEN) Suggests It's 47% Undervalued

Dec 09

Here's Why We're Not At All Concerned With Seagen's (NASDAQ:SGEN) Cash Burn Situation

Oct 14

Analyse de la rémunération des PDG

Comment la rémunération de David Epstein a-t-elle évolué par rapport aux bénéfices de Seagen?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2023	n/a	n/a	-US$750m
Jun 30 2023	n/a	n/a	-US$725m
Mar 31 2023	n/a	n/a	-US$649m
Dec 31 2022	US$59m	US$190k	-US$610m

Rémunération vs marché: La rémunération totale de David ($USD 58.59M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 12.66M ).

Rémunération et revenus: Données insuffisantes pour comparer la rémunération de David avec les performances de l'entreprise.

PDG

David Epstein (61 yo)

1.1yrs

Titularisation

US$58,588,196

Compensation

Mr. David R. Epstein, B.Sc., M.B.A., serves as Chief Executive Officer and Director at Seagen Inc. since November 9, 2022. He served as an Independent Director at Senti Biosciences, Inc. since June 09, 202...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
David Epstein	CEO & Director	1.1yrs	US$58.59m	0.0087% $ 3.8m
Todd Simpson	Chief Financial Officer	18.2yrs	US$5.71m	0.049% $ 21.3m
Vaughn Himes	Chief Technical Officer	7.3yrs	US$4.54m	0.071% $ 30.7m
Jean I. Liu	Chief Legal Officer & Corporate Secretary	9.1yrs	US$5.95m	0.026% $ 11.2m
Charles Romp	Executive Vice President of Commercial U.S.	3.7yrs	US$5.03m	0.037% $ 15.8m
Roger Dansey	Chief Medical Officer and President of Research & Development	1.1yrs	US$36.39m	0.020% $ 8.8m
William Compton	Senior VP of Global Information Technology & CIO	less than a year	pas de données	pas de données
David Caouette	Vice President of Corporate Communications	no data	pas de données	pas de données
Matt Skelton	Vice President of Marketing	8.1yrs	pas de données	pas de données
Peggy Pinkston	Chief Human Resources Officer	less than a year	pas de données	pas de données
Natasha Hernday	Chief Business Officer	1.2yrs	pas de données	pas de données
Megan O'Meara	Head of Early Stage Development & VP	no data	pas de données	pas de données

2.4yrs

Durée moyenne de l'emploi

61yo

Âge moyen

Gestion expérimentée: L'équipe de direction de SGEN est considérée comme expérimentée (ancienneté moyenne 2.4 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
David Epstein	CEO & Director	1.1yrs	US$58.59m	0.0087% $ 3.8m
John Orwin	Independent Director	9.9yrs	US$468.53k	0.015% $ 6.6m
David Gryska	Independent Director	18.8yrs	US$483.53k	0.026% $ 11.2m
Daniel Welch	Independent Director	16.5yrs	US$468.53k	0.0082% $ 3.5m
Felix Baker	Independent Chair of the Board	20.4yrs	US$528.53k	0.022% $ 9.5m
Ted Love	Independent Director	3.3yrs	US$471.03k	0.0025% $ 1.1m
Nancy Simonian	Independent Director	11.8yrs	US$474.53k	0.033% $ 14.4m
Alpna Seth	Independent Director	5.8yrs	US$471.03k	0.0069% $ 3.0m
Sandra Swain	Independent Director	1.1yrs	US$214.73k	pas de données

9.9yrs

Durée moyenne de l'emploi

62yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de SGEN sont considérés comme expérimentés (ancienneté moyenne 9.9 ans).

Seagen Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Chief Technical Officer notifies of intention to sell stock

Chief Technical Officer notifies of intention to sell stock

Insider notifies of intention to sell stock

Chief Technical Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Recent updates

Seagen Inc. Files Form 15

Seagen Inc.(NasdaqGS:SGEN) dropped from FTSE All-World Index (USD)

Pfizer Inc. (NYSE:PFE) completed the acquisition of Seagen Inc. (NasdaqGS:SGEN) from Baker/Tisch Investments, L.P, a funds managed by Baker Brothers Investments and others.

Seagen Inc.'s (NASDAQ:SGEN) Popularity With Investors Is Under Threat From Overpricing

Seagen Inc. Announces Phase 2 Study Evaluating the Antibody-Drug Conjugate ADCETRIS (brentuximab Vedotin) in Combination with the PD-1 Inhibitor Nivolumab and Standard Chemotherapy Agents Doxorubicin and Dacarbazine

Seagen Inc. Announces Data from the Phase 3 HER2CLIMB-02 Clinical Trial of TUKYSA

Astellas Pharma Inc. and Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application of Padcev with Keytruda for First-Line Treatment of Advanced Bladder Cancer

Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Chief Technical Officer notifies of intention to sell stock

Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Seagen Inc. Announces to Highlight Overall Survival Data for Padcev and Tivdak During Presidential Symposium At Esmo Congress 2023

Seagen Inc. to Report Q3, 2023 Results on Nov 01, 2023

Astellas Pharma Inc. and Seagen Inc. Announces Positive Topline Results from the Phase 3 Ev-302 Clinical Trial

Chief Technical Officer notifies of intention to sell stock

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Insider notifies of intention to sell stock

Seagen Inc. Announces Phase 3 HER2CLIMB-02 Clinical Trial of TUKYSA®? (tucatinib) in Combination with Antibody-Drug Conjugate Ado-Trastuzumab Emtansine

Consensus EPS estimates fall by 12%, revenue upgraded

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Seagen Inc. to Report Q2, 2023 Results on Aug 02, 2023

Seagen Inc. Announces Phase 3 Trial of Adcetris (Brentuximab Vedotin) with Modified Chemo Regimen Shows Non-Inferiority with Unprecedented 3-Year Progression Free Survival of 94.9% Vs Less Tolerable International Standard of Care in Advanced Classical Hodgkin Lymphoma

Seagen Announces ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate in Patients with Early-Stage Classical Hodgkin Lymphoma (cHL)

Chief Technical Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Independent Director notifies of intention to sell stock

First quarter 2023 earnings: EPS misses analyst expectations

Price target increased by 7.3% to US$216

Insider notifies of intention to sell stock

A Look At The Fair Value Of Seagen Inc. (NASDAQ:SGEN)

Chief Financial Officer exercised options and sold US$8.8m worth of stock

Independent Director notifies of intention to sell stock

Here's Why We're Not At All Concerned With Seagen's (NASDAQ:SGEN) Cash Burn Situation

Price target increased by 7.7% to US$181

Chief Financial Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Consensus EPS estimates fall by 22%

Independent Director exercised options to buy US$1.4m worth of stock.

Full year 2022 earnings: EPS and revenues exceed analyst expectations

President of Research & Development notifies of intention to sell stock

President of Research & Development notifies of intention to sell stock

Chief Legal Officer notifies of intention to sell stock

Seagen Inc. to Report Q4, 2022 Results on Feb 15, 2023

President of Research & Development notifies of intention to sell stock

Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

Independent Director exercised options to buy US$1.1m worth of stock.

Seagen Inc. Announces Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) with Novel Immunotherapy Combination in Patients with Advanced- and Early-Stage Classical Hodgkin Lymphoma

An Intrinsic Calculation For Seagen Inc. (NASDAQ:SGEN) Suggests It's 47% Undervalued

Price target decreased to US$166

Chief Legal Officer exercised options to buy US$171k worth of stock.

Independent Director recently sold US$968k worth of stock

Seagen Inc. Announces U.S. FDA Approval of New Indication for Adcetris® (Brentuximab Vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma

Price target decreased to US$169

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Seagen Inc. Revises Revenue Guidance for the Full Year of 2022

Chief Medical Officer & Interim CEO notifies of intention to sell stock

Here's Why We're Not At All Concerned With Seagen's (NASDAQ:SGEN) Cash Burn Situation

Seagen Inc. to Report Q3, 2022 Results on Oct 27, 2022

Seagen: A Stellar Portfolio Anchor

Seagen in licensing deal with Lava Therapeutics for cancer candidate

Seagen Inc. Announces TUKYSA® (tucatinib) in Combination with Trastuzumab Granted Priority Review by FDA for Previously Treated HER2-Positive Metastatic Colorectal Cancer

Seagen ticks lower as management suggests it could look at acquisitions

Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV(R) (Enfortumab Vedotin-Ejfv) with KEYTRUDA((R) (Pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer

Seagen to Highlight Research in Urothelial and Colorectal Cancers At 2022 European Society for Medical Oncology (Esmo) Congress

Chief Medical Officer & Interim CEO notifies of intention to sell stock

Merck’s Reportedly Talks to Acquire Seagen Hit Snag, Threatening Mega Pharma Deal

Merck's talks with Seagen said to hit obstacle over price - report